M&A
Deals relating to genomics increased in the pharmaceutical industry in H2 2021
The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.
Deals relating to genomics in the pharmaceutical sector have seen an increase, an analysis of GlobalData's deals database reveals.
Powered by
In the second half of 2021 the number of deals relating to genomics increased by 12.9% from the same period in 2020.
This marks an acceleration in growth from the 50.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.
GlobalData's deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.
During second half of 2021, deals relating to genomics accounted for 5.9% of all deals taking place in the sector. This represents an increase from the figure of 4.1% in second half of 2020
GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.
These themes, of which genomics is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.
